ESTRO 2024 - Abstract Book

S918

Clinical - CNS

ESTRO 2024

neutropenia (1.6%) and thrombocytopenia (1.6%). In patients treated with regorafenib, median PFS was 3 months (95% confidence interval: 3-5 months) and median OS was 20 months (95% confidence interval: 18-24 months). In the multivariate analysis, no statistically significant correlation was found between toxicity outcomes and radiotherapy treatment volumes.

Conclusion:

In our update of an observational real-world study, there were no statistically significant correlations between adverse events, including oedema and seizures and clinical or dosimetric parameters,such as treatment volume.Tolerability profile was manageable, with fatigue occurring most commonly, with potential impact on quality of life. Available literature data, from real life experiences, confirm the same OS and PFS data.

Keywords: Glioblastoma, recurrence